-+ 0.00%
-+ 0.00%
-+ 0.00%

EU Commission approves Roche Susvimo for wet age-related macular degeneration

PUBT·09/21/2026 16:18:46
Listen to the news
EU Commission approves Roche Susvimo for wet age-related macular degeneration
  • European Commission cleared Roche’s Susvimo (ranibizumab) for neovascular age-related macular degeneration in the EU.
  • Approval enables use of the Contivue refillable eye implant, positioned as an alternative to regular anti-VEGF injections.
  • Phase III Archway data showed vision outcomes matched monthly intravitreal ranibizumab, with dosing as few as two refills yearly.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roche Holding AG published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609211145OMX_____CNEWS_EN_GNW1001273840_en) on September 21, 2026, and is solely responsible for the information contained therein.